Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
130.4 USD | +2.20% | +0.90% | +19.59% |
May. 02 | Merck: encouraging results in gastric cancer | CF |
May. 01 | Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.02% | 323B | B- | ||
+31.52% | 690B | C+ | ||
+24.32% | 546B | B | ||
-5.21% | 358B | C+ | ||
+5.01% | 287B | C+ | ||
+13.94% | 235B | B+ | ||
+4.87% | 199B | B- | ||
-10.22% | 195B | A+ | ||
+3.98% | 161B | C+ | ||
-2.19% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRK Stock
- Ratings Merck & Co., Inc.